Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson’s day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption
Authors:
Open Access
- 10 September 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1619850
Abstract
Background: Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) has expanded the treatment options in advanced Parkinson’s disease (aPD). However, the most appropriate therapeutic setting for therapy implementation is not clear.Objective: To present a concept for LDp/CDp therapy implementation in a Parkinson’s day-clinic and efficacy and safety outcome data from patients under the new therapeutic regimen.Methods: Retrospective clinical data were collected from the first 24 patients with aPD who were initiated on LDp/CDp treatment at the Hamburg Parkinson’s day-clinic. Outcome parameters were analyzed in terms of motor symptoms (MDS -UPDRS II-IV), safety aspects and effects on patients’ quality of life (PDQ-39).Results: The concept of the Parkinson’s Day-clinic enabled the successful implementation of LDp/CDp therapy in patients with advanced Parkinson’s disease (aPD). It provided individualized medical supported via neurologists, specialized nurses and therapists and thus facilitated the transition from clinic-based care to home-based support. Compared to previous optimized oral treatment, the application of LDp/CDp significantly reduced motor complications such as dyskinesias and motor fluctuations by 53% on the MDS-UPDRS IV (p = 0.0094). Motor function improvements were paralleled by a numerical increase in activities of daily living scores (MDS-UPDRS II) and improvement in long-term mobility (PDQ-39 mobility subscale), suggesting potential benefits in daily functioning and perceived mobility.Conclusion: The value of our data is limited by its retrospective design and small sample size. However, the data suggest that a proper day-clinic setting enables the successful implementation of subcutaneous LDp/CDp therapy with improvement of motor functions and reduction of side effects. It also ensures the necessary intensive medical support and offers comprehensive device-related and psychosocial guidance for both patients and caregivers.Keywords
This publication has 27 references indexed in Scilit:
- Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's DiseaseMovement Disorders Clinical Practice, 2025
- Definition and diagnosis of Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of NeurologyJournal of Neurology, 2024
- Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/FoscarbidopaMovement Disorders Clinical Practice, 2024
- Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s diseaseJournal of Neural Transmission, 2022
- Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's DiseaseAnnals of Neurology, 2021
- The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient careJournal of Neural Transmission, 2018
- Medical and surgical management of advanced Parkinson's diseaseMovement Disorders, 2018
- Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter studyMovement Disorders, 2013
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008